{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:26:40Z","timestamp":1790267200736,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.08.005","type":"journal-article","created":{"date-parts":[[2018,8,28]],"date-time":"2018-08-28T18:03:12Z","timestamp":1535479392000},"page":"e32-e37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature"],"prefix":"10.1016","volume":"17","author":[{"given":"Anders","family":"Overby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Ladekarl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britt Elmedal","family":"Laursen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1016\/j.clgc.2018.08.005_bib1","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib2","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1200\/JCO.2002.04.019","article-title":"Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site","volume":"20","author":"Culine","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","article-title":"Carcinomas of an unknown primary origin--diagnosis and treatment","volume":"8","author":"Massard","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrclinonc.2017.97","article-title":"Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary","volume":"14","author":"Moran","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrclinonc.2016.194","article-title":"Diagnosis: improved diagnosis, therapy and outcomes for patients with CUP","volume":"14","author":"Greco","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4143\/crt.2012.44.3.215","article-title":"Metastatic renal cell carcinoma in a supraclavicular lymph node with no known primary: a case report","volume":"44","author":"Choi","year":"2012","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2018.08.005_bib7","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.3747\/co.21.1914","article-title":"Metastatic renal cell carcinoma without evidence of a primary renal tumour","volume":"21","author":"Kumar","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bjoms.2009.11.012","article-title":"Metastatic cutaneous head and neck renal cell carcinoma with no known primary: case report","volume":"48","author":"Bhatia","year":"2010","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.clgc.2018.08.005_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1477-7819-8-18","article-title":"Renal cell cancer without a renal primary","volume":"8","author":"Wayne","year":"2010","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11255-015-1145-3","article-title":"Metastatic renal\u00a0cell carcinoma without evidence of a renal primary","volume":"48","author":"Costantino","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clgc.2018.08.005_bib11","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3171\/2014.6.SPINE13448","article-title":"Metastatic renal cell carcinoma, with a radiographically occult primary tumor, presenting in the operative site of a thoracic meningioma: long-term follow-up: case report","volume":"21","author":"Heary","year":"2014","journal-title":"J\u00a0Neurosurg Spine"},{"key":"10.1016\/j.clgc.2018.08.005_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-212685","article-title":"Genomic characterisation of two cancers of unknown primary cases supports a kidney cancer origin","volume":"2015","author":"Wei","year":"2015","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clgc.2018.08.005_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000339130","article-title":"Papillary renal carcinoma presenting as a cancer of unknown primary (CUP) and diagnosed through gene expression profiling","volume":"5","author":"Sorscher","year":"2012","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s13730-016-0239-9","article-title":"Metastatic renal cell carcinoma with undetectable renal mass presenting as lymphadenopathy","volume":"6","author":"Fayaz","year":"2017","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.clgc.2018.08.005_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1440-1827.2011.02780.x","article-title":"Extra-renal clear cell renal cell carcinoma probably arising from mesodermal embryonic remnants","volume":"62","author":"Terada","year":"2012","journal-title":"Pathol Int"},{"key":"10.1016\/j.clgc.2018.08.005_bib16","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1159\/000167851","article-title":"Metastasizing renal cell carcinoma developing in a congenital ectopic and dysplastic kidney","volume":"81","author":"Akkad","year":"2008","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2018.08.005_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1442-2042.2011.02904.x","article-title":"Metastatic clear cell renal cell carcinoma to the adrenal gland without an identifiable primary tumor","volume":"19","author":"Johnson","year":"2012","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2018.08.005_bib18","first-page":"50","article-title":"Papillary renal cell carcinoma presented with supraclavicular lymph node metastasis without renal primary lesion","volume":"4","author":"Thamcharoen","year":"2013","journal-title":"World J Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib19","doi-asserted-by":"crossref","first-page":"e713","DOI":"10.1016\/j.clgc.2016.11.004","article-title":"Role of molecular profiling in diagnosis of papillary renal-cell cancer presenting as cancer of unknown primary site","volume":"15","author":"Nagasaka","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.08.005_bib20","doi-asserted-by":"crossref","first-page":"e893","DOI":"10.1016\/j.clgc.2018.03.001","article-title":"Renal cell carcinoma presenting as carcinoma of unknown primary site: recognition of a treatable patient subset","volume":"16","author":"Greco","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2018.08.005_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nrc2502","article-title":"The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer","volume":"8","author":"Kaelin","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clgc.2018.08.005_bib22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.08.005_bib23","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2018.08.005_bib25","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-14-0193","article-title":"PD-1 blockade in renal cell carcinoma: to equilibrium and beyond","volume":"2","author":"Harshman","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clgc.2018.08.005_bib26","article-title":"Prediction of primary tumors in cancers of unknown primary","volume":"14","author":"Sondergaard","year":"2017","journal-title":"J\u00a0Integr Bioinform"},{"key":"10.1016\/j.clgc.2018.08.005_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib29","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non\u2013clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2018.08.005_bib30","unstructured":"Hamieh L, McKay RR, Lin X, Simantov R, Choueiri TK. Characterization of patients with poor-risk metastatic renal-cell carcinoma: results from a pooled clinical trials database. Clin Genitourin Cancer. In press."},{"key":"10.1016\/j.clgc.2018.08.005_bib31","first-page":"123","article-title":"Spontaneous regression of renal cell carcinoma","volume":"17","author":"Janiszewska","year":"2013","journal-title":"Contemp Oncol (Pozn)"},{"key":"10.1016\/j.clgc.2018.08.005_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/CCO.0b013e32835f085d","article-title":"Extragonadal germ cell tumors: clinical presentation and management","volume":"25","author":"Albany","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clgc.2018.08.005_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000478050","article-title":"Treatment outcomes for metastatic melanoma of unknown primary in the new era: a single-institution study and review of the literature","volume":"93","author":"Utter","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2018.08.005_bib34","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2018.08.005_bib35","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303616?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318303616?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:24Z","timestamp":1761564744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318303616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1558767318303616"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.005","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}